deltatrials
Completed PHASE3 INTERVENTIONAL 3-arm NCT03633617

Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)

A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)

Sponsor: Regeneron Pharmaceuticals

Conditions Eosinophilic Esophagitis
Interventions Dupilumab Placebo
Updated 26 times since 2018 Last updated: Jun 2, 2023 Started: Sep 24, 2018 Primary completion: Sep 9, 2021 Completion: Jun 7, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03633617, this PHASE3 trial focuses on Eosinophilic Esophagitis and remains completed. Sponsored by Regeneron Pharmaceuticals, it has been updated 26 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Sep 2018 – ~Dec 2018 · 3 months · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Apr 2019 · 59 days · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Jul 2019 · 2 months · monthly snapshot~Jul 2019 – ~Nov 2019 · 4 months · monthly snapshot~Nov 2019 – ~Feb 2020 · 3 months · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~May 2020 · 2 months · monthly snapshot~May 2020 – ~Aug 2020 · 3 months · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Dec 2020 · 2 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~May 2021 · 3 months · monthly snapshot~May 2021 – ~Jan 2022 · 8 months · monthly snapshot~Jan 2022 – ~May 2022 · 4 months · monthly snapshot~May 2022 – ~Sep 2022 · 4 months · monthly snapshot~Sep 2022 – ~Feb 2023 · 5 months · monthly snapshot~Feb 2023 – ~Jul 2023 · 5 months · monthly snapshot~Jul 2023 – ~Jul 2024 · 12 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

26 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jul 2023 — Jul 2024 [monthly]

    Completed PHASE3

  5. Feb 2023 — Jul 2023 [monthly]

    Completed PHASE3

▶ Show 21 earlier versions

  1. Sep 2022 — Feb 2023 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  2. May 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE3

  3. Jan 2022 — May 2022 [monthly]

    Active Not Recruiting PHASE3

  4. May 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  5. Feb 2021 — May 2021 [monthly]

    Recruiting PHASE3

  6. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE3

  7. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  8. Oct 2020 — Dec 2020 [monthly]

    Recruiting PHASE3

  9. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE3

  10. Aug 2020 — Sep 2020 [monthly]

    Recruiting PHASE3

  11. May 2020 — Aug 2020 [monthly]

    Recruiting PHASE3

  12. Mar 2020 — May 2020 [monthly]

    Recruiting PHASE3

  13. Feb 2020 — Mar 2020 [monthly]

    Recruiting PHASE3

  14. Nov 2019 — Feb 2020 [monthly]

    Recruiting PHASE3

  15. Jul 2019 — Nov 2019 [monthly]

    Recruiting PHASE3

  16. May 2019 — Jul 2019 [monthly]

    Recruiting PHASE3

  17. Apr 2019 — May 2019 [monthly]

    Recruiting PHASE3

  18. Feb 2019 — Apr 2019 [monthly]

    Recruiting PHASE3

  19. Jan 2019 — Feb 2019 [monthly]

    Recruiting PHASE3

  20. Dec 2018 — Jan 2019 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  21. Sep 2018 — Dec 2018 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Regeneron Pharmaceuticals
  • Sanofi
Data source: Regeneron Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands , Ann Arbor, United States , Aurora, United States , Barcelona, Spain , Barnsley, United Kingdom , Boise, United States , Boston, United States , Bristol, United States , Bruges, Belgium , Camperdown, Australia and 79 more locations